Granted Patent B2

US 8,128,960 · App. 12/401,168 · Granted Mar 6, 2012

Abstract

Claims (14)

1. An aqueous suspension composition particularly suited for injection into the eye, wherein the suspension composition does not contain a preservative, has a pH from 6-7.5, a viscosity of 2-12 cps, and a Degree of Flocculation of about 9.5 or greater, and wherein the suspension composition consists essentially of:

a) 4% (w/v) triamcinolone acetonide having a mean volume diameter of 3-10 μm;

b) 0.5% (w/v) sodium carboxymethylcellulose;

c) 0.002-0.015% (w/v) polysorbate 80;

d) one or more pharmaceutically acceptable chloride salts selected from the group consisting of sodium chloride, potassium chloride. calcium chloride, and magnesium chloride as tonicity-adjusting agents in a total amount sufficient to cause the suspension composition to have an osmolality from 250-350 mOsm;

e) a buffering agent;

f) water for injection; and

g) optionally a pH-adjusting agent.

2. The suspension composition of claim 1 wherein the sodium carboxymethylcellulose has a molecular weight such that a 2% (w/v) solution of the sodium carboxymethylcellulose in water at 25° C. has a viscosity of 25-50 cps.

3. The suspension composition of claim 1 wherein the concentration of polysorbate 80 is 0.015% (w/v).

4. The suspension composition of claim 1 wherein the suspension composition comprises 0.4-0.6% (w/v) sodium chloride, 0.05-0.1% (w/v) potassium chloride, 0.04-0.06% (wlv) calcium chloride, and 0.01-0.04% (w/v) magnesium chloride.

5. The suspension composition of claim 1 wherein the buffering agent comprises sodium acetate and sodium citrate.

6. The suspension composition of claim 1 wherein the suspension composition has a viscosity of 2-9 cps.

7. The suspension composition of claim 6 wherein the suspension composition has a viscosity of 2-8 cps.

Assignments (9)